Besides, CysC level was also a useful predictor for early neurological deterioration in AIS patients (17) and short-term outcomes for AIS patients after intravenous tissue plasminogen activator (IV-tPA) therapy (16). This evidence concerns the gene PLAT and androgen insensitivity syndrome.